Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.57 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SDHB | P21912 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271821 | 0.87 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1KMT2AATMKDM4E | |
| SCHEMBL21928846 | 0.82 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1NOS3NOS2NOS1 | |
| SCHEMBL14387653 | 0.79 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1KMT2AATMKDM4E | |
| SCHEMBL21731003 | 0.79 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1KMT2AATMKDM4E | |
| SCHEMBL15726902 | 0.79 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1ATMKDM4EHSD17B10 | |
| SCHEMBL10271822 | 0.79 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1KMT2AATMKDM4E | |
| SCHEMBL16579591 | 0.79 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1KMT2AATMKDM4E | |
| SCHEMBL12871593 | 0.78 | NOS3 (0.46) | HSP90AA1HSP90AB1NOS3NOS2NOS1 | |
| SCHEMBL21212748 | 0.77 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1KMT2AATMKDM4E | |
| SCHEMBL18299043 | 0.77 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1NOS3NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024033322-A1 | METAL COMPLEX, SEMICONDUCTOR LAYER COMPRISING A METAL COMPLEX AND ORGANIC ELECTRONIC DEVICE | NOVALED GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023072273-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | 先声再明医药有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3686199-B9 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2022-12-07 | — | — | EP | disclosed |
| EP-3611174-B1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2022-06-08 | — | — | EP | disclosed |
| US-11312715-B2 | Fused ring derivative as A2A receptor inhibitor | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| WO-2022012409-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-01-20 | — | — | WO | disclosed |
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2021-09-14 | — | — | US | disclosed |
| US-11066411-B2 | — | — | 2021-07-20 | — | — | US | disclosed |
| US-20200239465-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| WO-2016079711-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079710-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079709-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC | 2016-01-28 | — | — | US | disclosed |
| US-9149527-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| WO-2015037680-A1 | HETEROCYCLIC AMIDE COMPOUND AND HERBICIDE | 日産化学工業株式会社 (JP) | 2015-03-19 | — | — | WO | disclosed |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8722731-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130140539-A1 | HOST MATERIAL AND ORGANIC LIGHT EMITTING DISPLAY DEVICE USING THE SAME | LG DISPLAY CO., LTD. (KR) | 2013-06-06 | — | — | US | disclosed |
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312715-B2 | Fused ring derivative as A2A receptor inhibitor | ADORA2A, ADORA2B, ADORA1 | HSP90AA1 3780/4885HSP90AB1 3681/4885NOS3 2625/4885 |
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, EIF4A1 | HSP90AA1 1066/4885HSP90AB1 947/4885NOS3 3093/4885 |
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | ADORA2A, ADORA1, ADORA3 | HSP90AA1 4395/4885HSP90AB1 4394/4885NOS3 2162/4885 |
| US-20200239465-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA2B, ADORA1 | HSP90AA1 3780/4885HSP90AB1 3681/4885NOS3 2625/4885 |
| US-11066411-B2 | — | ADORA2A, ADORA1, ADORA2B | HSP90AA1 4106/4885HSP90AB1 4149/4885NOS3 2128/4885 |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | HSP90AA1 1262/4885HSP90AB1 1167/4885NOS3 3105/4885 |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | HSP90AA1 1262/4885HSP90AB1 1167/4885NOS3 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.